In the eye of the storm: the right ventricle in COVID-19.
John F ParkSomanshu BanerjeeSoban UmarPublished in: Pulmonary circulation (2020)
The corona virus disease of 2019 pandemic caused by the SARS-CoV-2 virus continues to inflict significant morbidity and mortality around the globe. A variety of cardiovascular presentations of SARS-CoV-2 infection have been described so far. However, the impact of SARS-CoV-2 on the right ventricle is largely unknown. Due to its pathophysiologic relevance, the right ventricle finds itself in the eye of the storm of corona virus disease of 2019, placing it at higher risk of failure. Increased afterload from acute respiratory distress syndrome and pulmonary embolism, negative inotropic effects of cytokines, and direct angiotensin converting enzyme 2-mediated cardiac injury from SARS-CoV-2 are potential mechanisms of right ventricle dysfunction in corona virus disease of 2019. Early detection and treatment of right ventricle dysfunction may lead to decreased mortality and improved patient outcomes in corona virus disease of 2019.
Keyphrases
- sars cov
- pulmonary embolism
- respiratory syndrome coronavirus
- pulmonary artery
- pulmonary hypertension
- acute respiratory distress syndrome
- mitral valve
- coronavirus disease
- angiotensin converting enzyme
- angiotensin ii
- extracorporeal membrane oxygenation
- type diabetes
- congenital heart disease
- heart failure
- coronary artery disease
- cardiovascular disease
- disease virus
- inferior vena cava
- climate change
- smoking cessation